ipilimumab
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
October, 2024
October 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Sep
ipilimumab
Oct 20, 2024, 17:47 |
Drugs
Stephen V Liu: Long-term survival with nivolumab and ipilimumab in advanced NSCLC
Stephen V Liu shared on X: "Long-term survival (median f/u 73.7m) with nivolumab and ipilimumab…
Oct 8, 2024, 15:29 |
Insight
Jarushka Naidoo: Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab in NSCLC
Jarushka Naidoo shared a post on X: “Long-Term Outcomes 1L Ipilimumab/Nivolumab/-Chemo v Chemo in PDL1<1%…
Oct 2, 2024, 15:14 |
Blog
Suraj Samtani: Real-World Study of first Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma
Suraj Samtani, Medical Oncologist at Harvard Medical School, shared a post on X, about recent…
Sep 27, 2024, 16:31 |
Insight
Immunotherapy for aggressive breast cancer appears to be effective even without chemotherapy - The Netherlands Cancer Institute
The Netherlands Cancer Institute posted on LinkedIn: "Immunotherapy as a treatment for an aggressive form of…
Sep 26, 2024, 14:05 |
Blog
Stephen V Liu: Real-world study of first-line nivolumab and ipilimumab for pleural mesothelioma
Stephen V Liu shared a post on X, about recent paper published in Clinical Lung…
Sep 21, 2024, 15:21 |
Insight
Ulrike Harjes: Promising response rates with Nivolumab in TNBC patients
Ulrike Harjes, Senior Editor at Nature Medicine, posted the following on X: “Out now in Nature…
Sep 21, 2024, 13:13 |
Blog
Florian Lordick: Niche2 data presented by Myriam Chalabi
Florian Lordick, Professor of Medicine at University of Leipzig and Director of the Comprehensive Cancer…
Sep 21, 2024, 09:03 |
Blog
Neoadjuvant nivolumab with or without ipilimumab in early stage TNBC
Top Biomedical Science shared a post on X, about recent paper published in Nature Medicine:…
Sep 18, 2024, 14:14 |
Blog
Petros Grivas: Ipilimumab/nivolumab vs standard care in non-clear cell renal cell cancer by Andrea Apolo
Petros Grivas shared a post by Andrea Apolo on X: "Agree with Andrea Apolo excellent…
Sep 17, 2024, 16:15 |
Blog
Median overall survival in melanoma with nivolumab plus ipilimumab presented at ESMO24 - NEJM
NEJM posted the following on X: “Presented at ESMO24: Among patients with advanced melanoma, median…
Sep 15, 2024, 23:34 |
Insight
Insights from ESMO24 Day 2
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 12, 2024, 14:42 |
Insight
Colon Cancer Treatment: NICHE-2 Validates Immunotherapy
Maria Babak shared a post by The Babak Lab on LinkedIn: “ This research highlights…
Sep 7, 2024, 08:54 |
Insight
Ipilimumab or Relatlimab Plus Nivolumab in Advanced Melanoma
Marco Donia shared a post on LinkedIn: "Ipilimumab Plus Nivolumab or Relatlimab Plus Nivolumab in…
Sep 5, 2024, 18:09 |
Blog
How biomarkers can predict patients' responses to ICI treatments - CRI
CRI (Cancer Research Institute) shared a post on LinkedIn: ''Led by CRI Scientific Advisory Council…
Sep 2, 2024, 08:35 |
Insight
Shilpa Gupta: Novel approach of intermittent IO in mRCC
Shilpa Gupta shared a post on X by María Natalia Gandur Quiroga about a recent…
Sep 1, 2024, 10:46 |
Insight
Article of the day, September 1st, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 26, 2024, 04:06 |
Blog
Article of the Day, August 25th, suggested by IMMONC
Immune Oncology Research Institute made the following post on LinkedIn: “Article of the day suggested…
Aug 12, 2024, 07:28 |
Dialogues
Immunotherapy in Soft Tissue - 5 min Sarcoma Talk #6 with Sandra D'Angelo
In the new episode of "5 Minute Sarcoma Talk", Dr. Shushan Hovsepyan, the Editor-in-Chief of…
Aug 7, 2024, 01:22 |
Insight
8 years of follow-up in the CheckMate 214 trial
Yüksel Ürün shared a paper by Nizar M. Tannir et al. on X: "Nivolumab +…
Aug 6, 2024, 13:44 |
Blog
The Nobel Prize: "Without him my kids wouldn’t be here" - cancer survivor Sharon Belvin
The Nobel Prize shared a post on LinkedIn: " 'Without him [Nobel Prize laureate James…
Aug 2, 2024, 11:14 |
Insight
Razelle Kurzrock: Our newest DART study
Razelle Kurzrock shared a post by the Journal for ImmunoTherapy of Cancer on X, adding:…
Jul 21, 2024, 08:52 |
Blog
Ece Tolgay: I will be presenting a poster at the ECI2024
Ece Tolgay, Member of American Association of Immunologists, posted on X: …
Jul 9, 2024, 07:25 |
Insight
Piotr Wysocki: Checkpoint inhibitor and TKI combinations in GU malignancies
Piotr Wysocki recently posted on LinkedIn: "A phase I study (Apolo AB et al. J Clin…
Jul 6, 2024, 07:58 |
Drugs
Tanja Obradovic: Important lesson in development of the PDL-1 inhibitor just came in
Tanja Obradovic posted on LinkedIn: "Important lesson in the development of the PDL-1 inhibitor just…
Jul 5, 2024, 15:03 |
Drugs
Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours
Andrea Apolo, Chief of Bladder Cancer Section Genitourinary Malignancies Branch Center for Cancer Research at…
Jul 5, 2024, 13:47 |
Insight
Andrea Apolo: Very proud of this Clinical Trial of Cabozantinib/Nivolumab published at JCO
Shilpa Gupta shared a post by Andrea Apolo, adding: "Huge congrats Andrea Apolo, leading this…
Jul 5, 2024, 02:30 |
Drugs
Ipilimumab and Nivolumab for patients with unresected advanced Hepatocellular Carcinoma - ESMO
ESMO shared on LinkedIn: "Benefits reported for the combination of ipilimumab and nivolumab further expand…
Jul 3, 2024, 00:52 |
Blog
Hedyeh Ebrahimi: Intrigued by the difference in response between CBM588 and ctrl arms
Hedyeh Ebrahimi, Postdoctoral fellow at Genitourinary Cancer Research Team of City of Hope shared a…
Jun 30, 2024, 14:51 |
Insight
Sergio Cifuentes: Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about…
Jun 8, 2024, 09:58 |
Insight
Angelo Pirozzi: Circulating immune-related proteins might predict the efficacy of Immune Checkpoint Inhibitors
Angelo Pirozzi, Research Fellow at Mayo Clinic, shared on X: .…
Jun 8, 2024, 06:59 |
Blog
Results of the NICHE-2 trial show it to be highly effective in a subset of patients with colon cancer - The Netherlands Cancer Institute
The Netherlands Cancer Institute shared on Linkedin: “More succes for neoadjuvant immunotherapy: results of the…
Jun 5, 2024, 04:04 |
Drugs
Jon Wigginton: Very exciting phase 3 data regarding stage 3 melanoma
Jon Wigginton, President of Research and Development at Bright Peak Therapeutics, shared on LinkedIn: “NEJM…
Jun 4, 2024, 13:13 |
Insight
Tanja Obradovic: NADINA trial making history at ASCO2024 plenary session
Tanja Obradovic shared on LinkedIn: . "NADINA trial making history today at ASCO2024 plenary session.…
Jun 2, 2024, 23:47 |
Insight
NADINA is one of the 11 clinical studies with the biggest impact on health care in 2024 - Netherlands Cancer Institute
Quoting The Netherlands Cancer Institute on LinkedIn: "The NADINA study, led by researchers from the…
Jun 2, 2024, 09:37 |
Insight
Allison Betof Warner: Relativity-048 presented by Paolo A. Ascierto at ASCO24
Allison Betof Warner, Director of Melanoma Medical Oncology and Solid Tumor Cellular Therapy at Stanford…
May 31, 2024, 15:03 |
Insight
CheckMate 648 review by Erman Akkus
Erman Akkus, Medical Oncologist at Ankara University, shared on X: "First line Nivolumab plus ChT…
May 28, 2024, 07:49 |
Insight
Tom Powles: Renal cancer highlights at ASCO24 - KIM1 biomarker data stands out
Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and…
May 24, 2024, 13:24 |
Insight
Erman Akkus Summarizes 5-year Results of CheckMate 040
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X: “Nivolumab plus ipilimumab…
May 23, 2024, 00:35 |
Drugs
Toni Choueiri: The story of adaptive IO therapy in RCC
Toni Choueiri recently shared a post by Rana McKay, an Associate Professor of Medicine at…
May 14, 2024, 15:36 |
Insight
Andy Hahn: Congrats to Ana Aparicio and team on this trial of 192 men with mCRPC
Andy Hahn, Genitourinary Medical Oncologist at MD Anderson Cancer Center, shared on X: “Congratulations to…
May 12, 2024, 07:27 |
Drugs
Tanja Obradovic summarizes the latest news on immunotherapy with chemoradiation NSCLC
Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON, shared on LinkedIn: “Based on what…
Apr 28, 2024, 11:04 |
Blog
Ana I. Velázquez Mañana: ASCO24 abstract titles are out! Exciting Plenary Session, specially for LCSM community
Ana I. Velázquez Mañana shared on X/Twitter: “ASCO24 abstract titles are out! Exciting Plenary Session, specially…
Apr 25, 2024, 19:53 |
Blog
Razelle Kurzrock: SWOG has given us the opportunity to do a national immunotherapy trial for rare tumors
Razelle Kurzrock, Chair of Precision Oncology at MCW Cancer Center, shared a post by SWOG…
Mar 31, 2024, 08:44 |
Blog
UCLA Health Jonsson Comprehensive Cancer Center's presentation at the annual meeting of the American Association for Cancer Research (AACR)
Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will discuss the latest breakthroughs and cutting-edge science…
Feb 2, 2024, 17:33 |
Drugs
Day 3 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers recently tweeted: "Day 3 of GU24 ASCO Highlights 1. KN564: Adj Pembro w/…
Nov 26, 2023, 17:27 |
Insight
Marco Donia: Most combinations in oncology have additive but not synergistic efficacy
Marco Donia, Clinical Research Associate Professor at University of Copenhagen, shared on LinkedIn: "Most combinations…
Oct 31, 2023, 09:39 |
Insight
Paolo A. Ascierto: The history of melanoma is changing!
Paolo A. Ascierto, Director Department of Melanoma/Skin Cancers, Cancer Immunotherapy and Development Therapeutics at IRCCS,…
Sep 25, 2023, 16:07 |
Insight
Steven O'Day: Today is World Cancer Research Day, which is a good day for me to share three things.
Quoting Steven O'Day, the Chief Medical Officer at Agenus, on LinkedIn: "Today is World Cancer…
All:
48
Posts:
1 - 100
Making Personal Experience a Political Priority: Insights from EU Commissioner Stella Kyriakides
Zolbetuximab is now approved by the US FDA
Highlights from NFCR’s GSAC24
SIOP Honoured Hansjörg Riehm with the 2024 Lifetime Achievement Award
Margaret Foti has received the 2024 Beacon Award for Women Leaders in Oncology
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube